今日药学

2021, v.31(11) 857-860

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

我院替格瑞洛相关不良反应的分析
Analysis of Adverse Drug Reactions Induced by Ticagrelor in Our Hospital

林东兰;罗利琼;陈健达;邝植雄;
LIN Donglan;LUO Liqiong;CHEN Jianda;KUANG Zhixiong;Department of Pharmacy,Taishan People's Hospital;

摘要(Abstract):

目的监测替格瑞洛的不良反应,为其安全用药提高参考。方法对2020年4~9月在我院首次服用替格瑞洛的195例患者进行为期1年的随访,分析其服药后的ADR情况。结果 195例患者中有23例(11.79%)发生27例替格瑞洛相关的药物不良反应(ADR),发生时间最快为首次服药后2 h,最迟为36 w,绝大多数(18例,66.67%)发生在2 w内,症状多为轻、中度;主要累及器官/系统为呼吸系统(59.26%);主要临床表现为呼吸困难12例(44.44%)和轻微出血10例(37.04%);1例呼吸困难可能与ARB能增加替格瑞洛相关呼吸困难风险有关;1例血透患者使用替格瑞洛无不适症状。结论替格瑞洛安全性高,较少严重的不良反应,但由于其在我国上市晚,在药物相互作用及特殊人群用药方面缺少循证医学证据。药师应加强临床用药监测,重视药物相互作用,减少药物不良反应,确保临床用药安全。
OBJECTIVE To monitor adverse drug reactions(ADR) induced by ticagrelor, and provide reference for safe drug use. METHODS 195 patients received ticagrelor firstly in our hospital from April 2020 to September 2020 were followed-up for 1 year, and the ADR situation was analyzed and summarized after taking drug. RESULTS In the 195 patients, 23 patients(11.79%) suffered from 27 cases of ticagrelor-related ADR.The earliest occurrence time was 2 hours after the first administration, and the latest was 36 weeks later.The vast majority(18 cases, 66.67%) occurred within 2 weeks.And the symptoms were mostly mild or moderate.The mainly involved organ/system was respiratory system(59.26%).The main clinical manifestations were dyspnea(44.44%) and eminor bleeding(37.04%).One case of dyspnea might be related to ARB,which was an added risk for developing dyspnea on ticagrelor.One patient of hemodialysis had no discomfort after taking drug. CONCLUSION Ticagrelor has good safety and little serious ADR.But due to its shorter time to market in China and lack of evidence-based medicine in drug interactions and drug use for special population, pharmacists should strengthen clinical medication monitoring and pay attention to drug interactions to reduce the ADR and ensure clinical medication safety.

关键词(KeyWords): 替格瑞洛;不良反应;分析;基层医院
ticagrelor;adverse drug reaction;analysis;the basic level hospital

Abstract:

Keywords:

基金项目(Foundation): 江门市卫生计生局科研立项项目(江卫函[2020]256号-20A135)

作者(Author): 林东兰;罗利琼;陈健达;邝植雄;
LIN Donglan;LUO Liqiong;CHEN Jianda;KUANG Zhixiong;Department of Pharmacy,Taishan People's Hospital;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享